Report overview
Bendamustine hydrochloride injection is a cytotoxic drug used to treat chronic lymphoblastic leukemia and non Hodgkin's lymphoma.
This report contains market size and forecasts of Bendamustine Hydrochloride Injection in global, including the following market information:
Global Bendamustine Hydrochloride Injection Market Revenue, 2018-2023, 2023-2030, ($ millions)
Global Bendamustine Hydrochloride Injection Market Sales, 2018-2023, 2023-2030, (K Units)
Global top five Bendamustine Hydrochloride Injection companies in 2022 (%)
The global Bendamustine Hydrochloride Injection market was valued at million in 2022 and is projected to reach US$ million by 2030, at a CAGR of % during the forecast period 2023-2030.
The U.S. Market is Estimated at $ Million in 2022, While China is Forecast to Reach $ Million by 2030.
25mg Bottle Segment to Reach $ Million by 2030, with a % CAGR in next six years.
The global key manufacturers of Bendamustine Hydrochloride Injection include Eagle Pharmaceuticals, Teva Pharmaceutical Industries, Cephalon, Hospira, Mylan, Apotex, Fresenius Kabi, Seacross Pharmaceuticals and Nanjing King-Friend, etc. In 2022, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Bendamustine Hydrochloride Injection manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Bendamustine Hydrochloride Injection Market, by Type, 2018-2023, 2023-2030 ($ Millions) & (K Units)
Global Bendamustine Hydrochloride Injection Market Segment Percentages, by Type, 2022 (%)
25mg Bottle
100mg Bottle
Global Bendamustine Hydrochloride Injection Market, by Application, 2018-2023, 2023-2030 ($ Millions) & (K Units)
Global Bendamustine Hydrochloride Injection Market Segment Percentages, by Application, 2022 (%)
Chronic Lymphocytic Leukemia
Non Hodgkin'S Lymphoma
Global Bendamustine Hydrochloride Injection Market, By Region and Country, 2018-2023, 2023-2030 ($ Millions) & (K Units)
Global Bendamustine Hydrochloride Injection Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Bendamustine Hydrochloride Injection revenues in global market, 2018-2023 (Estimated), ($ millions)
Key companies Bendamustine Hydrochloride Injection revenues share in global market, 2022 (%)
Key companies Bendamustine Hydrochloride Injection sales in global market, 2018-2023 (Estimated), (K Units)
Key companies Bendamustine Hydrochloride Injection sales share in global market, 2022 (%)
Further, the report presents profiles of competitors in the market, key players include:
Eagle Pharmaceuticals
Teva Pharmaceutical Industries
Cephalon
Hospira
Mylan
Apotex
Fresenius Kabi
Seacross Pharmaceuticals
Nanjing King-Friend
Yangtze River Pharmaceutical Group
Kindos Pharma
Chongqing Huapont Pharm
Simcere Pharmaceutical Group
